Cold Agglutinin Disease

Autoimmune Hemolytic Anemia

Bendamustine, Rituximab

Herlev University Hospital

Turku University Hospital

Haukeland University Hospital

Vestre Viken Hospital

Haugesund Hospital

Akershus University Hospital

Oslo University Hospital

St Olav University Hospital

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy

Responses will be assessed using the following, previously published definitions:
Complete response (CR), Absence of anemia, no signs of hemolysis, no clinical symptoms of CAD, undetectable serum monoclonal protein, and no signs of clonal lymphoproliferation by bone marrow histology, immunohistochemistry and flow cytometry.
Partial response (PR), Stable increase in hemoglobin levels by at least 2.0 g/dL or to the normal range, combined with a reduction of serum IgM concentrations by at least 50% or to the normal range, improvement of clinical symptoms, and transfusion independency.
Non-response (NR), Patients not meeting the criteria for CR or PR.

Time to response (TTR) is the time from start of therapy to the achievement of any degree of response.

Time to best response (TTBR) is the time from start of therapy to the observation of the highest hemoglobin level achieved + 0.5 g/dL.

Response duration is the time from achievement of any degree of response to relapse. Relapse is defined by one or more of the following events: A decline in hemoglobin level by at least 2.0 g/dL from the highest level achieved or to below 10.0 g/dL; transfusion requirement; or recurrence of significant cold-induced circulatory symptoms.

Data are to be shared between authors before final analysis and publication.

Sigbjorn Berentsen

MD, PhD

Helse Fonna

Rituximab

Fludarabine

Ullevaal University Hospital

Rikshospitalet-Radiumhospitalet University Hospital

Sykehuset i Vestfold

BMT Clinic, St Petersburg Pavlov State Medical University

Therapy for Chronic Cold Agglutinin Disease

Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine.

cobalamine/vėžys

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

Therapy for Chronic Cold Agglutinin Disease

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu